neflamapimod

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dementia With Lewy Bodies (DLB)

Conditions

Dementia With Lewy Bodies (DLB)

Trial Timeline

Oct 16, 2024 → Apr 1, 2026

About neflamapimod

neflamapimod is a phase 2 stage product being developed by CervoMed for Dementia With Lewy Bodies (DLB). The current trial status is active. This product is registered under clinical trial identifier NCT06815965. Target conditions include Dementia With Lewy Bodies (DLB).

What happened to similar drugs?

6 of 20 similar drugs in Dementia With Lewy Bodies (DLB) were approved

Approved (6) Terminated (1) Active (13)
🔄[18F]NAV4694Navidea BiopharmaceuticalsPhase 3
E2020 + PlaceboEisaiApproved
🔄ARICEPTEisaiPhase 3
🔄donepezil hclEisaiPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06815965Phase 2Active

Competing Products

20 competing products in Dementia With Lewy Bodies (DLB)

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 3
26
AL001 + Placebo + Open label - AL001AlectorPhase 3
22
AL001AlectorPhase 2
25
ATH-1017 + PlaceboLeonaBioPhase 2
17
IGC AD1 + PlaceboIGC PharmaPhase 1
19
E2020 + PlaceboEisaiApproved
43
ARICEPTEisaiPhase 3
40
RasagilineEisaiPhase 2
35
Donepezil HydrochlorideEisaiPre-clinical
26
donepezil hclEisaiPhase 3
40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
40
E2020 + E2020EisaiPhase 2
35
donepezil hydrochloride (Aricept)EisaiApproved
43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
35
E2020 + E2020EisaiPhase 3
40
Irsenontrine + PlaceboEisaiPhase 2
35
E2020EisaiPhase 2
35
MecobalaminEisaiApproved
43
E2020 + PlaceboEisaiPhase 3
40
Donepezil HydrochlorideEisaiPhase 3
40